LLY

732.84

+0.49%↑

JNJ

176.84

+0.16%↑

ABBV

208.2

+0.17%↑

UNH

304.08

-0.96%↓

AZN

79.96

+0.05%↑

LLY

732.84

+0.49%↑

JNJ

176.84

+0.16%↑

ABBV

208.2

+0.17%↑

UNH

304.08

-0.96%↓

AZN

79.96

+0.05%↑

LLY

732.84

+0.49%↑

JNJ

176.84

+0.16%↑

ABBV

208.2

+0.17%↑

UNH

304.08

-0.96%↓

AZN

79.96

+0.05%↑

LLY

732.84

+0.49%↑

JNJ

176.84

+0.16%↑

ABBV

208.2

+0.17%↑

UNH

304.08

-0.96%↓

AZN

79.96

+0.05%↑

LLY

732.84

+0.49%↑

JNJ

176.84

+0.16%↑

ABBV

208.2

+0.17%↑

UNH

304.08

-0.96%↓

AZN

79.96

+0.05%↑

Search

Innoviva Inc

Open

SectorHealthcare

19.9 0.1

Overview

Share price change

24h

Current

Min

19.61

Max

19.98

Key metrics

By Trading Economics

Income

110M

64M

Sales

12M

100M

P/E

Sector Avg

34.667

35.724

Profit margin

63.508

Employees

127

EBITDA

111M

84M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+103.69% upside

Dividends

By Dow Jones

Next Earnings

4 Nov 2025

Market Stats

By TradingEconomics

Market Cap

78M

1.2B

Previous open

19.8

Previous close

19.9

News Sentiment

By Acuity

36%

64%

115 / 372 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Innoviva Inc Chart

Past performance is not a reliable indicator of future results.

Related News

26 Aug 2025, 23:56 UTC

Earnings

WiseTech Lifts Dividend as Its Annual Profit Rises 30% -- Update

26 Aug 2025, 23:48 UTC

Earnings

Woolworths Annual Profit Falls, Cuts Dividend

26 Aug 2025, 23:41 UTC

Earnings

WiseTech Lifts Dividend as Its Annual Profit Rises 30%

26 Aug 2025, 23:58 UTC

Earnings

China Resources Land: Real-Estate Sector Faces Structural Challenges, but Homebuying Demand Gradually Returning >1109.HK

26 Aug 2025, 23:57 UTC

Earnings

China Resources Land: 1H Results Buoyed by Investment Property & Asset Management Business >1109.HK

26 Aug 2025, 23:55 UTC

Earnings

China Resources Land 1H Net CNY11.88B Vs. Net CNY10.22B >1109.HK

26 Aug 2025, 23:55 UTC

Earnings

China Resources Land 1H Rev CNY94.92B Vs. CNY79.19B >1109.HK

26 Aug 2025, 23:48 UTC

Earnings

Karoon Energy Interim Dividend 2.4 Australian Cents/Security

26 Aug 2025, 23:47 UTC

Earnings

Karoon Energy 1H Underlying Net Profit US$45 Million, Down 61% on Year

26 Aug 2025, 23:47 UTC

Earnings

Karoon Energy 1H Revenue US$308.3 Million, Down 25% on Year

26 Aug 2025, 23:47 UTC

Earnings

Karoon Energy 1H Net Profit US$71 Million, Up 15% on Year

26 Aug 2025, 23:46 UTC

Market Talk

Nikkei May Trade in Range Amid US Tariff Uncertainty -- Market Talk

26 Aug 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments -- Market Talk

26 Aug 2025, 23:35 UTC

Earnings

Karoon Energy Expects Expenditure of US$80 Million-US$90 Million Over 2030-2034

26 Aug 2025, 23:35 UTC

Earnings

Karoon Energy Expects Expenditure of US$55 Million-US$65 Million for Projects in 2026

26 Aug 2025, 23:34 UTC

Earnings

Karoon Energy: Baúna Revitalization, Life Extension Projects Initiated

26 Aug 2025, 23:34 UTC

Earnings

Karoon Energy: Baúna Project Economic Field Life Extends to 2039

26 Aug 2025, 23:33 UTC

Earnings

Karoon Energy Raises Baúna Project 2P Reserves by 13.7 Million Bbls

26 Aug 2025, 23:23 UTC

Earnings

WiseTech: FY25 Ebitda Margin Exit Run Rate 52%>WTC.AU

26 Aug 2025, 23:22 UTC

Earnings

WiseTech: New CargoWise Commercial Model Ready for Rollout>WTC.AU

26 Aug 2025, 23:21 UTC

Earnings

WiseTech Says Integration of e2open Is on Track>WTC.AU

26 Aug 2025, 23:14 UTC

Earnings

WiseTech Expects FY26 Ebitda Margin of 40-41%>WTC.AU

26 Aug 2025, 23:13 UTC

Earnings

WiseTech Expects FY26 Ebitda Growth of 44-53%>WTC.AU

26 Aug 2025, 23:13 UTC

Earnings

WiseTech Expects FY26 Ebitda of $550M-$585M>WTC.AU

26 Aug 2025, 23:13 UTC

Earnings

WiseTech Expects FY26 Revenue Growth of 79-85%>WTC.AU

26 Aug 2025, 23:12 UTC

Earnings

WiseTech Expects FY26 Revenue of $1.39B-$1.44B>WTC.AU

26 Aug 2025, 23:11 UTC

Earnings

WiseTech FY Ebitda Margin Ex-e2open Costs 53%>WTC.AU

26 Aug 2025, 23:11 UTC

Earnings

WiseTech FY Ebitda Margin 49% Vs. 48%>WTC.AU

26 Aug 2025, 23:10 UTC

Earnings

WiseTech FY Ebitda $381.6M Vs. $325.0M>WTC.AU

26 Aug 2025, 23:09 UTC

Earnings

WiseTech Global Declares Dividend of $0.077 >WTC.AU

Peer Comparison

Price change

Innoviva Inc Forecast

Price Target

By TipRanks

103.69% upside

12 Months Forecast

Average 40.25 USD  103.69%

High 55 USD

Low 26 USD

Based on 4 Wall Street analysts offering 12 month price targets forInnoviva Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

18.57 / 18.75Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

115 / 372 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.